PDS Biotech will participate in

FLORHAM PARK, NJ, May 17, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing a growing portfolio of molecular-targeted cancer immunotherapies and infectious disease vaccines based on the company’s exclusive Versamune technology® and Infectimune™ T-cell activation technologies, announced today that its leadership will present at the HC Wainwright Global Investment Conference and LD Micro Invitational and participate in the UBS Healthcare Virtual One-on-One Day.

HC Wainwright Global Investment Conference
Date: Tuesday, May 24, 2022
Time: 7:00 a.m. EDT
Investors can register for the conference here

UBS Healthcare Virtual One-on-One Day
Date: Wednesday, June 1, 2022

Conference by invitation LD Micro
Date: Wednesday, June 8, 2022
Time: 7:30 a.m. PDT
Virtual viewers: Direct

At the end of the conferences, a replay webcast of the presentations will be available on the Investors section of the company’s website, PDS Biotechnology.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted immunotherapies for cancer and infectious diseases based on the company’s proprietary Versamune® and Infectimune™ T-cell activation technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing live, large amounts of high quality and very potent polyfunctional CD4+ and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and attack and destroy them effectively. The Company’s pipeline products treat various cancers, including HPV16-associated cancers (anal, cervical, head and neck, penis, vaginal, vulvar) and breast, colon, lung, prostate and cervical cancers. ‘ovary.

Our Infectimune™-based vaccines have demonstrated the potential to induce not only robust and long-lasting neutralizing antibody responses, but also potent T-cell responses, including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Investor contacts:
rich rooster
CG Capital
Phone: +1 (404) 736-3838
[email protected]

PDS-Biotechnology-Corporation.png

About Tina G.

Check Also

Mumbai could see triangle fight in civic polls | Bombay News

The Mumbai led rebellion Eknath Shinde in Shiv Sena changed the political equations in Maharashtra. …